Skip to main content

Table 1 Clinical trial efficacy results of novel single-agent treatments

From: Therapeutic options in peripheral T cell lymphoma

Agent Targeting site Phase No. of evaluable patients Type of patients Outcomes ClinicalTrial.gov ID References
Tipifarnib Farnesyltransferase inhibitor II 12 PTCL 50 % ORR NCT00082888 [49]
Darinaparsin Organic arsenic compound II 7 PTCL 28.6 % ORR, 3.6 months median TTF, 6.4 months OS NCT00421213 [50]
Panobinostat Pan-deacetylase inhibitor II 139 CTCL 17.3 % ORR NCT00425555 [51]
Denileukin diftitox Interleukin fusion protein III 263 CTCL 38 % ORR, median DoR was 277 days NCT00050999 [52]
NCT00051012
Ixazomib Proteasome inhibitor I 4 PTCL 1 PR NCT00893464 [53]
Sorafenib Multikinase inhibitor 12 PTCL/CTCL 42 % ORR, 4 CR, 1 PR [54]
Forodesine PNP inhibitor II 101 CTCL No CR, 11 % PR, 50 % SD, median DoR was 191 days NCT00501735 [55]
  1. ORR overall response rate, CR complete response, PR partial response, SD stable disease, TTF time to treatment failure, OS overall survival, DoR duration of response, PNP purine nucleoside phosphorylase